Drug

Enoximone

As of the edition of 20 October 2026, Enoximone is a small molecule: marketed, first approved in 1987 (FR); acts on PDE3A and PDE3B.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1987
Kind
Small molecule
Brand name
Perfane
First approved
27 October 1987 (FR)
Approvals on record
1 in 1 region
Holder of the most recent approval
CARINOPHARM (ALLEMAGNE)
Registered trials
5, 3 stopped early
Disease areas
Heart and blood vessels; Infections

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Targets

GeneProteinUniProt
PDE3BcGMP-inhibited 3',5'-cyclic phosphodiesterase 3BQ13370
PDE3AcGMP-inhibited 3',5'-cyclic phosphodiesterase 3AQ14432

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 33102
Phase 42001
All trials5